Significant benefit seen for neoadjuvant tislelizumab plus chemotherapy with adjuvant tislelizumab

Improved median overall survival and progression-free survival seen for pegargiminase-based chemotherapy

Greater incidence of grade 3 or higher adverse events from any cause seen in combination group versus monotherapy

Improvement in overall survival seen for patients receiving cisplatin or carboplatin with pemetrexed

More patients taking alectinib with low-fat yogurt do not reach the exposure threshold of 435 ng/mL

In phase 2 trial, overall survival longer with combo treatment compared with investigator's choice for standard of care in advanced NSCLC

Drug was to be used alongside chemotherapy for patients with metastatic non-small cell lung cancer

No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease

Objective response seen in 37.1 percent of patients with previously treated KRAS p.G12C-mutated non-small cell lung cancer

Lumakras is approved for use in adults with KRAS G12C-mutated non-small cell lung cancer